Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2713–2736 of 13,629 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatoses Clear all

Conditions: Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer, Prostate, Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
Interventions: SYS6043; Drug
Lead sponsor: Conjupro Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Plantation, Florida • Austin, Texas • San Antonio, Texas + 1 more

Conditions: Breast Cancer
Interventions: questionnaire administration, digital mammography, positron emission mammography; Other · Procedure
Lead sponsor: Boston Medical Center; Other
Eligibility: 35 Years and older · Female only
Enrollment: 193 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ependymoma, Ewing Sarcoma, High-grade Glioma, Leukemia and Lymphoma, Medulloblastoma, Miscellaneous Brain Tumors, Miscellaneous Solid Tumors, Neuroblastoma, Relapsed, Refractory Malignant Neoplasms, Rhabdomyosarcoma
Interventions: Nivolumab, NKTR-214; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Up to 30 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Little Rock, Arkansas • St Louis, Missouri

Conditions: TNBC, TNBC - Triple-Negative Breast Cancer, TNBC, Triple Negative Breast Cancer
Interventions: leronlimab (PRO 140); Drug
Lead sponsor: CytoDyn, Inc.; Industry
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Salem, Oregon

Conditions: Onychomycosis, Dermatophytosis
Interventions: Jublia (Efinaconazole 10% Topical Solution); Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Metastatic Breast Cancer, HER2-negative Breast Cancer
Interventions: Dapagliflozin 10Mg Tab; Drug
Lead sponsor: Saint Luke's Health System; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Breast Cancer
Interventions: fat reduction with increased fiber, fat reduction without increased fiber; Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 50 Years to 69 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2004
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Psoriasis
Interventions: UV-B Lightsource and Fiber Optic Comb; Device
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions: Autologous cultured dermal and epidermal cells; Biological
Lead sponsor: Aderans Research Institute; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Houston, Texas

Conditions: Breast Cancer
Interventions: Radiation; Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 19 Years to 99 Years · Female only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 3
States / cities: New York, New York

Conditions: Melanoma, Renal Cell Carcinoma, Sarcoma, Breast Cancer, Lung Cancer, Colorectal Cancer, Gastrointestinal Cancers, Brain Metastases
Interventions: Gamma Knife Radiosurgery; Procedure
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Breast Cancer
Interventions: Cardiac SPECT perfusion scan; Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Non-small Cell Lung Cancer, Colorectal Cancer, Breast Cancer
Interventions: Guardant360; Diagnostic Test
Lead sponsor: Guardant Health, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Skokie, Illinois

Conditions: Breast Cancer
Interventions: ferumoxtran-10, magnetic resonance imaging, sentinel lymph node biopsy; Drug · Procedure
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Actinic Keratosis
Interventions: Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%, Vehicle, Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E.; Drug · Other · Device
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 22
States / cities: Phoenix, Arizona • Fremont, California • Castle Rock, Colorado + 19 more

Conditions: Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Independent (Primary) Multiple Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx, Malignant Neoplasms of Male Genital Organs, Malignant Neoplasms of Mesothelial and Soft Tissue, Malignant Neoplasms of Respiratory and Intrathoracic Organs, Malignant Neoplasms of Thyroid and Other Endocrine Glands, Malignant Neoplasms of Urinary Tract
Interventions: Pembrolizumab, Clostridium Novyi-NT, Doxycycline; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Gastrointestinal Cancer, Neuroendocrine Carcinoma, Skin Cancer
Interventions: Aromatherapy and Essential Oils, Subject Diary; Procedure · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Lymphedema
Interventions: Strength training; Behavioral
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 295 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Melanoma
Interventions: DC Vaccine + IFN, AdVTMM2/DC Vaccination; Biological
Lead sponsor: Lisa H. Butterfield, Ph.D.; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Metastatic Triple Negative Breast Cancer
Interventions: Carboplatin, Nab-paclitaxel, Pembrolizumab; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Psoriasis, Plaque Psoriasis, Insulin Resistance, PreDiabetes, Overweight and Obesity
Interventions: Oral glucose tolerance test (OGTT), Skin punch biopsy; Diagnostic Test · Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Cardiac Toxicity, Cardiovascular Complications
Interventions: trastuzumab, doxorubicin hydrochloride, polymorphism analysis, laboratory biomarker analysis, questionnaire administration, assessment of therapy complications, magnetic resonance imaging; Biological · Drug · Genetic + 2 more
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 4
States / cities: Louisville, Kentucky • Nashville, Tennessee

Conditions: Netherton Syndrome
Interventions: QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle, QRX003-4% Lotion BID; Drug
Lead sponsor: Quoin Pharmaceuticals; Industry
Eligibility: 14 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 5
States / cities: San Diego, California • Indianapolis, Indiana • Quincy, Massachusetts + 2 more

Conditions: Angioedema, Hereditary, Types I and II
Interventions: KVD824, Placebo to KVD824; Drug
Lead sponsor: KalVista Pharmaceuticals, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 13
States / cities: Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 10 more

Search by objective public record fields.

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

Positron Emission Mammography and Standard Mammography in Women at High Risk of Breast Cancer

A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)

Study Evaluating the Effect of Jublia on Dermatophytomas

Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer

Diet and Estrogen Metabolism in Postmenopausal Women

Scalp Psoriasis Treatment With a Fiber Optic Comb

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss

Accelerated Radiation Therapy (ART) to the Breast and Nodal Stations

A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection

Assessment of Ability of Breath Hold for Left-sided Breast Cancer Radiation Therapy to Reduce Side Effects to Heart

SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation

Magnetic Resonance Imaging Using Ferumoxtran-10 in Finding Metastases to the Axillary Lymph Nodes in Patients With Breast Cancer

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities

Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT

Inhaled Essential Oil Effect on Common QOL Concerns During Cancer Treatment

Strength Training Intervention for Breast Cancer Survivors and the Effects on Lymphedema Status

Multiple Antigen-Engineered DC Vaccine for Melanoma

Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer

Role of Insulin Action in Psoriasis Pathogenesis

Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab

Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II